Small Cap Feast

Small Cap Feast – 30 September 2019

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 878

Total number of AIM Companies trading: 796*
* As at 30 September 2019

Set Menu NEX Growth:

Total number of NEX Growth Market Companies (Incl Susp): 88*

Total number of NEX Growth Market Companies trading: 86*
* As at 30 September 2019

Set Menu Standard List:

Total number of Standard List Companies (Incl Susp): 165*

Total number of Standard List Companies trading: 143*
* As at 30 September 2019

Dish of the Day:

Entertainment AI (EAI) – This was an RTO into Blockchain Worldwide (BLOC), It has also transferred from the standard list to AIM. Focused on providing its global automotive and lifestyle audiences and its strategic partner audiences with real-time access, in a frictionless way, to “in the moment” opportunities from more relevant short form video content to “one-click” e-commerce, £8.6m raised.  H1 2019 actuals – GTChannel subsidiary’s MCN gross advertising revenue at $8.7 m, up 107%

Off the Menu:

Goals Soccer Centres has left AIM.

Dish of the Day:

No Joiners Today

Off the Menu:

No Leavers Today

What’s Cooking in the IPO Kitchen?

Main Market Standard
Kaspi.kz, the largest Payments, Marketplace and Fintech Ecosystem in Kazakhstan with a leading market share in each of its key products and services. GDR offering expected Oct 2019. In the first half of 2019, the Company generated total revenue of KZT226,862m (U.S. $598m), up 34% and net income of KZT77,001m (U.S. $203m), up 54%
Main Market premium
Registration document approved for Helios Towers. The Group provides essential network services, flexible infrastructure solutions and reliable power supply to mobile network operators in five African growth economies. Revenue increased 7 per cent. year-on-year to

Breakfast Buffet

Altitude Group (ALT) 53.4p £36.7m

Altitude Group, the operator of a leading m a r k e t p l a c e f o r p e r s o n a l i s e d products, announces its unaudited results for the six months ended 30 June 2019.
Highlights
Revenue growth of 43% to £5.4m (H1 2018: £3.8m)
Gross profit up 78% to £3.7m (H1 2018: £2.1m)
Adjusted operating profit* of £0.3m (H1 2018 loss: £0.3m)
Loss before taxation £0.9m (H1 2018 loss: £0.7m)
Successful integration of the AI Mastermind business acquired in January 2019, renamed AIM Smarter LLC
Accelerated US hiring and training process complete across all divisions; sales, marketing, technology, customer service and accounting
AIM membership and aggregate member annual revenues increased by 14% to 2,185 and 12% to circa $2.1 billion respectively since acquisition
161 suppliers now signed up to our Preferred Supplier Program
92 members upgraded to enhanced services

mporium Group (MPM) 0.5p £5.2m

Mporium Group, the technology firm delivering event-driven marketing, announced that it has entered into non-binding heads of terms for the acquisition of the entire issued share capitals of Click Laboratories Limited and We Breathe M ed ia L t d , t w o companies under substantially common ownership operating a performance-based digital agency focused on the design, build and delivery of end-to-end multi-channel lead generation campaigns, f o r a m ax im u m consideration of £5.5m.
Highlights
Click Labs specialises in email-marketing as well as providing critical technology, tools and know-how to optimise lead generation performance which is highly complementary to Mporium’s expertise in search, social and display marketing
Potential Acquisition expected to make a material positive contribution to the Group’s performance in FY2019 and onwards, and is expected to accelerate Mporium’s pathway to becoming net cash generative
The initial cash consideration and Potential Acquisition and ongoing working capital needs of the Group are proposed to be financed by an issue of new Ordinary Shares to existing and new investors to raise £1.25 million

Physiomics* (PYC) 2.75p £1.98m

Physiomics plc, a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that, based on its unaudited management accounts for the year ended 30 June 2019, the Company is trading in l i n e w i t h a n a l y s t expectations.
Total income (revenue and grant income) increased 53% to £783,101 (2018: £512,899)
The operating loss decreased 23% to £201,219 (2018 £260,391)
The loss after taxation decreased 43% to £104,040 (2018: £183,341)
Operational:
Agreements signed with Merck KGaA for £435,000 for consulting services in calendar year 2019
Addition of two new biotech clients, Convert P h a r m a c e u t i c a l s (Belgium) and Bicycle Therapeutics (UK)
Attendance at major conferences including EORTC-NCI-AACR (Dublin), Biotech Showcase (San Francisco), AACR (Atlanta), BioTrinity (London) and PAGE (Stockholm)
Presentation of posters at both the AACR and PAGE conferences
Signing of a strategic collaboration with the Medicines Discovery Catapult (Alderley Park, UK)

IQE (IQE) 65.4p £518m

IQE, the leading global supplier of advanced wafer products and materials s o l u t i o n s t o t h e semiconductor industry, a n n o u n c e s t h e successful device and module qualification for VCSEL epi-wafers for a major Asian OEM. This represents an important development in the adoption of 3D sensing technology by Android smartphones, with production volumes anticipated in 2020.
Vertical Cavity Surface Emitting Lasers (VCSELs) are a key component in multiple current and future 3D sensor systems, using both structured light and Time of Flight (ToF) technologies. Applications range from 3D Facial Identification (front facing) systems and world facing cameras on mobile handsets, to LiDAR and in cabin sensing for autonomous drive vehicles.
Production volumes are expected to ramp strongly over the next few years as adoption across multiple mobile platforms and other use cases proliferate. In anticipation of this strong growth, IQE has invested over the last two years in building the worlds’ largest VCSEL epi-wafer facility in Newport, UK (IQE’s Mega Epi Foundry).

Thor Mining* (THR) 0.44p £4.5

The Board of Thor Mining advises publication of a maid en Mineral Resource Estimate for the Big Sandy Lithium Deposit in Arizona, USA, by Hawkstone M i n i n g L i m i t ed (“Hawkstone”) (ASX: HWK).
Hawkstone, the 100% owner of the Big Sandy project, has announced an Indicated and Inferred Mineral Resource Estimate of 32.5m Tonnes grading 1,850 parts per million (ppm) Li, or 320,800 t o n n e s L i t h i u m Carbonate Equivalent, reported above an 800ppm Li cut-off.

Concepta* (CPT) 1.65p £4.4m

Concepta, the innovative UK personalised healthcare company and developer of the proprietary self-test platform (“myLotus®”), the most accurate home-use fertility tracking and pregnancy testing system available on the U.K. market, a n n o u n c e s t o d a y encouraging interim results, showing initial sales and scale up of its proprietary self-test platform, myLotus®, an improved cash position and a narrower loss for the period.
Further to Concepta’s interim results statement, we highlight a second positive announcement, in which it announces its first UK F e r t i l i t y C l i n i c collaboration with

Solid State PLC (SOLI) 497.2p £42.3m

Solid State, the AIM listed manufacturer of computing, power and communications products, and value added distributor of electronic components, announced an international contract win.
The contract, valued at $3m, has been won by the Group’s Pacer Optoelectronics business unit, acquired by Solid State in November 2018. The display project, a rail infrastructure programme in the United States, will utilise Pacer’s value added capabilities and is expected to be delivered over the next nine months.

Savannah Resources (SAV) 2.15p £28

Savannah Resources, the AIM quoted resource development company, announces that further to the recent placing and subscription to raise £3.76m(before e x p e n s e s ) , a s announced on 16 September 2019, Al Marjan Ltd, the Company’s largest shareholder, has now s u b s c r i b e d f o r 60,00 0,00 0 n ew ordinary shares of 1p each  in the Company (‘Ordinary Shares’) at a price of 2p per Ordinary Share, along with other subscribers raising cash proceeds of £1.24 million

Amryt Pharma PLC (AMYT) 133p £372m

Amryt Pharma put out an RNS today about their IR programme, a fairly long list of making the most of being l is t e d a n d p r et t y impressive, meetings such as; Cantor Fitzgerald Global Healthcare Conference,  New York, NY. Various S ha res M ag az i ne Investor Evenings, 2 x Proactive Investors One2One Investor F o r u m s , S t i f e l Healthcare Conference,  New York, NY and J e f f e r i e s G l o b a l Healthcare Conference,  London, UK.

Seeing Machines Ltd (SEE) 4.5p £151m

Seeing Machines Limited the leading provider of AIenabled driver monitoring technology for improved transport safety, advises that the Board has invited Paul McGlone, CEO, to participate in the S eeing M ac hi n es Employee Benefits Plan and has awarded rights in respect of a total of 37,000,000 ordinary shares of no par value in the Company (“Ordinary Shares”) .

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.